Vanguard Group’s Exact Sciences EXAS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $1.77B | Sell |
17,415,415
-393,062
| -2% | -$31.6M | 0.03% | 518 |
|
|
2025
Q3 | $974M | Sell |
17,808,477
-98,982
| -0.6% | -$4.95M | 0.01% | 719 |
|
|
2025
Q2 | $952M | Buy |
17,907,459
+269,785
| +2% | +$13.7M | 0.02% | 699 |
|
|
2025
Q1 | $764M | Buy |
17,637,674
+617,384
| +4% | +$31.3M | 0.01% | 776 |
|
|
2024
Q4 | $956M | Sell |
17,020,290
-743,624
| -4% | -$46.3M | 0.02% | 676 |
|
|
2024
Q3 | $1.21B | Sell |
17,763,914
-411,357
| -2% | -$23.2M | 0.02% | 598 |
|
|
2024
Q2 | $768M | Buy |
18,175,271
+435,179
| +2% | +$23.9M | 0.01% | 753 |
|
|
2024
Q1 | $1.23B | Buy |
17,740,092
+180,341
| +1% | +$11.4M | 0.02% | 588 |
|
|
2023
Q4 | $1.3B | Buy |
17,559,751
+115,058
| +0.7% | +$7.54M | 0.03% | 554 |
|
|
2023
Q3 | $1.19B | Sell |
17,444,693
-119,581
| -0.7% | -$10.1M | 0.03% | 539 |
|
|
2023
Q2 | $1.65B | Buy |
17,564,274
+171,986
| +1% | +$13.4M | 0.04% | 460 |
|
|
2023
Q1 | $1.18B | Buy |
17,392,288
+139,823
| +0.8% | +$8.99M | 0.03% | 542 |
|
|
2022
Q4 | $854M | Buy |
17,252,465
+575,854
| +3% | +$23.5M | 0.02% | 634 |
|
|
2022
Q3 | $542M | Buy |
16,676,611
+698,740
| +4% | +$28.8M | 0.02% | 789 |
|
|
2022
Q2 | $629M | Buy |
15,977,871
+335,877
| +2% | +$18M | 0.02% | 738 |
|
|
2022
Q1 | $1.09B | Buy |
15,641,994
+210,260
| +1% | +$15.4M | 0.03% | 606 |
|
|
2021
Q4 | $1.2B | Buy |
15,431,734
+64,700
| +0.4% | +$5.71M | 0.03% | 593 |
|
|
2021
Q3 | $1.47B | Sell |
15,367,034
-43,521
| -0.3% | -$4.6M | 0.04% | 506 |
|
|
2021
Q2 | $1.92B | Buy |
15,410,555
+307,132
| +2% | +$36.7M | 0.05% | 435 |
|
|
2021
Q1 | $1.99B | Buy |
15,103,423
+903,330
| +6% | +$124M | 0.05% | 395 |
|
|
2020
Q4 | $1.88B | Buy |
14,200,093
+770,797
| +6% | +$93.2M | 0.05% | 380 |
|
|
2020
Q3 | $1.37B | Sell |
13,429,296
-332,924
| -2% | -$28.8M | 0.05% | 422 |
|
|
2020
Q2 | $1.2B | Sell |
13,762,220
-6,652
| -0% | -$531K | 0.04% | 442 |
|
|
2020
Q1 | $799M | Buy |
13,768,872
+340,768
| +3% | +$27.7M | 0.03% | 504 |
|
|
2019
Q4 | $1.24B | Buy |
13,428,104
+1,564,834
| +13% | +$138M | 0.04% | 474 |
|
|
2019
Q3 | $1.07B | Buy |
11,863,270
+341,626
| +3% | +$38.9M | 0.04% | 496 |
|
|
2019
Q2 | $1.36B | Buy |
11,521,644
+309,043
| +3% | +$31.1M | 0.05% | 414 |
|
|
2019
Q1 | $971M | Buy |
11,212,601
+418,085
| +4% | +$35.6M | 0.04% | 509 |
|
|
2018
Q4 | $681M | Buy |
10,794,516
+296,429
| +3% | +$20.3M | 0.03% | 580 |
|
|
2018
Q3 | $829M | Buy |
10,498,087
+261,239
| +3% | +$17M | 0.03% | 574 |
|
|
2018
Q2 | $612M | Buy |
10,236,848
+4,102
| +0% | +$221K | 0.03% | 677 |
|
|
2018
Q1 | $413M | Buy |
10,232,746
+177,427
| +2% | +$8.66M | 0.02% | 846 |
|
|
2017
Q4 | $528M | Buy |
10,055,319
+339,454
| +3% | +$18.1M | 0.02% | 724 |
|
|
2017
Q3 | $458M | Buy |
9,715,865
+256,186
| +3% | +$10.3M | 0.02% | 762 |
|
|
2017
Q2 | $335M | Buy |
9,459,679
+700,051
| +8% | +$21.6M | 0.02% | 906 |
|
|
2017
Q1 | $207M | Buy |
8,759,628
+528,352
| +6% | +$10.5M | 0.01% | 1206 |
|
|
2016
Q4 | $110M | Buy |
8,231,276
+311,306
| +4% | +$5.03M | 0.01% | 1566 |
|
|
2016
Q3 | $147M | Buy |
7,919,970
+814,959
| +11% | +$14.4M | 0.01% | 1317 |
|
|
2016
Q2 | $87M | Buy |
7,105,011
+428,035
| +6% | +$3.22M | 0.01% | 1606 |
|
|
2016
Q1 | $45M | Sell |
6,676,976
-20,551
| -0.3% | -$131K | ﹤0.01% | 1915 |
|
|
2015
Q4 | $61.8M | Buy |
6,697,527
+168,353
| +3% | +$1.57M | ﹤0.01% | 1784 |
|
|
2015
Q3 | $117M | Buy |
6,529,174
+619,614
| +10% | +$14.2M | 0.01% | 1324 |
|
|
2015
Q2 | $176M | Buy |
5,909,560
+187,687
| +3% | +$4.71M | 0.01% | 1148 |
|
|
2015
Q1 | $126M | Buy |
5,721,873
+530,913
| +10% | +$13.5M | 0.01% | 1345 |
|
|
2014
Q4 | $142M | Buy |
5,190,960
+146,619
| +3% | +$3.57M | 0.01% | 1183 |
|
|
2014
Q3 | $97.8M | Buy |
5,044,341
+23,088
| +0.5% | +$423K | 0.01% | 1368 |
|
|
2014
Q2 | $85.5M | Buy |
5,021,253
+632,035
| +14% | +$8.7M | 0.01% | 1505 |
|
|
2014
Q1 | $62.2M | Buy |
4,389,218
+161,436
| +4% | +$2.18M | 0.01% | 1686 |
|
|
2013
Q4 | $49.4M | Buy |
4,227,782
+158,359
| +4% | +$1.82M | ﹤0.01% | 1794 |
|
|
2013
Q3 | $48.1M | Buy |
4,069,423
+195,830
| +5% | +$2.51M | ﹤0.01% | 1743 |
|
|
2013
Q2 | $53.9M | Buy |
+3,873,593
| New | +$42.1M | 0.01% | 1590 |
|
Other funds holding EXAS
HI
PCM
FCM
DKCM
Vanguard Group's EXAS Position: Q4 2025 in Review
Vanguard Group reduced its Exact Sciences (EXAS) stake by 2.2% in Q4 2025, selling an estimated $31.6M and leaving 17,415,415 shares worth $1.77B. The position accounts for 0.03% of the portfolio, ranked #518.
Vanguard Group first reported a position in EXAS in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.99B in Q1 2021. 711 funds tracked by Wall St. Rank hold EXAS as of Q4 2025.
- Vanguard Group held 17,415,415 shares of Exact Sciences worth $1.77B as of Q4 2025.
- Vanguard Group sold 393,062 Exact Sciences shares in Q4 2025, an estimated $31.6M.
- Exact Sciences made up 0.03% of Vanguard Group's portfolio in Q4 2025, its #518 holding.
- Vanguard Group first reported a position in Exact Sciences in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Exact Sciences position peaked at $1.99B in Q1 2021.
- 711 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.